Single-agent checkpoint inhibitors often fail to achieve durable responses in advanced or metastatic cancers. Combining synergistic pathways addresses the limitation of tumor immune evasion and low objective response rates.

Standard monotherapies often result in transient efficacy or incomplete tumor eradication. Coordinating multi-agent regimens and radiotherapy addresses the limitation of early treatment escape and acquired resistance.